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Background: Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) is primarily a treatment
option for medically inoperable patients, who are often elderly. However, few studies report the effects of SBRT in
elderly patients. Thus, we retrospectively analyzed clinical outcomes and feasibility following treatment of very elderly
patients (age ≥ 85 years) with stage Ι NSCLC and younger patients (age < 85 years) with SBRT in our institution.
Methods: From January 2006 to December 2012, 81 patients (20 very elderly; median age, 80 years; age range
64–93 years) with stage Ι NSCLC received SBRT. Prescription doses of 48 Gy were delivered in 4 fractions over
2 weeks or doses of 60 Gy were delivered in 10 fractions over 3 weeks.
Results: Local control was achieved in 91.8% of all patients at 3 years (83.1% and 93.8% of very elderly and
younger patients, respectively), and the 3-year overall survival (OS) rate was 69.4% (40.7% and 75.0% of very elderly
and younger patients, respectively). OS rates were significantly shorter for the very elderly group than for the younger
group, with a 3-year cause-specific survival (CSS) rate of 77.9% (50.4% and 81.6% of very elderly and younger
patients, respectively) and a 3-year progression-free survival (PFS) rate of 59.5% (44.7% and 63.5% in very elderly
and younger groups, respectively). Multivariate analysis revealed a significant correlation between T stage and OS.
Grades 2 and 3 radiation pneumonitis (RP) occurred in 7 (8.6%) and 2 (2.5%) patients, respectively. Among patients
of very elderly and younger groups, grade 2 RP occurred in 4 (20%) and 3 (4.9%) patients, and grade 3 occurred in
2 (10%) and 0 (0%) patients, respectively. No grade 4 or 5 toxicity was observed, RP was significantly more severe
among very elderly patients.
Conclusions: SBRT for stage Ι NSCLC was well tolerated and feasible in very elderly patients. The efficacy of SBRT
was comparable to that achieved in younger patients, although very elderly patients experienced significantly
more severe RP. Although this study cohort included only 20 very elderly patients, the present data suggest that
decreasing volumes of normal lung tissues exposed to ≥ 20 Gy and mean lung doses reduces the risk of RP in very
elderly patients. The present data warrant studies of larger very elderly cohorts.
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Numbers of elderly patients with non-small cell lung
cancer (NSCLC) are currently increasing [1]. However,
these patients are less likely to receive surgical resection
due to comorbid conditions, higher intraoperative risks,
and personal preference to avoid definitive surgery. Radio-
therapy offers a curative alternative for elderly patients
with NSCLC, although conventional radiotherapy is not
curative [2]. Silbley GS et al. showed that higher than
conventional doses of radiotherapy improved survival in
patients with medically inoperable stage I NSCLC [3].
Furthermore, stereotactic body radiotherapy (SBRT)
presents a promising treatment for patients with stage I
NSCLC who are medically inoperable or refuse surgery,
with improved efficacy and lower complication rates
[4-7]. Previously, the effectiveness of lobectomy, sublobar
resection, conventional radiotherapy, SBRT, and obser-
vation based treatment strategies were compared with
conventional radiotherapy in elderly patients. In this
study, overall survival (OS) was significantly improved
following SBRT and was similar to that after lobectomy
[8]. Other recent reports also indicate that SBRT is an
effective treatment option for the elderly (age ≥ 75 years),
with minimal toxicity [9-12] and similar OS outcomes to
those achieved with surgery [13]. According to reports
from Japanese institutions, SBRT is primarily performed
in medically inoperable NSCLC patients with median ages
of 76–78 years [14-17]. Japan has one of the world’s fastest
aging societies, with a mean life expectancy at birth of
83 years in 2011 (79 years for men and 86 years for
women) [18]. However, few studies report outcomes of
SBRT in elderly patients with NSCLC. Thus, in the
present study, we retrospectively analyzed clinical out-
comes and feasibility of SBRT in 20 very elderly pa-
tients (≥85 years) with stage Ι NSCLC who exceeded
the Japanese life expectancy at birth, and made com-
parisons with NSCLC patients of < 85 years.
Methods
Eligibility criteria
Eligibility criteria were as follows: (1) identification of
T1N0M0 or T2aN0M0 (stage Ι) primary lung cancer ac-
cording to the Union for International Cancer Control
in the 7th lung cancer TNM classification and staging
system using computed tomography (CT) of the chest
and upper abdomen, bone scintigraphy, and brain mag-
netic resonance imaging, (2) confirmation of NSCLC
from histology or clinical information such as increased
maximum standardized uptake valued (SUVmax) on
18-fluoro-deoxyglucose-positron emission tomography
(FDG-PET), tumor enlargement on CT images, or ele-
vated tumor marker levels during the observation
period, (3) predominantly peripheral localization of the
tumor, and (4) arterial oxygen pressure of ≥ 60 mmHgand predicted postoperative forced expiratory volume
of ≥ 700 ml at 1 s. These respiratory criteria are identical
to those prescribed by the Japan Clinical Oncology
Group 0403 [19]. Patients with medicated interstitial
pneumonia or a history of radiotherapy to the chest and
lungs were excluded, whereas age was not considered a
contraindication. Medical operability of tumors was
assessed by a multidisciplinary board. Our institutional
Medical Ethics Committee approved the treatment
protocol, and all patients submitted written informed
consent before inclusion in the study.
Patient characteristics
From January 2006 to December 2012, 81 patients with
stage Ι NSCLC received SBRT. Table 1 summarizes the
pretreatment characteristics of the 81 patients, who were
divided into age groups of very elderly (≥85 years; n = 20,
24.7%) and younger (<85 years; n = 61, 75.3%) patients.
The median age of all patients was 80 years (range, 64–93;
3 over 90 years), and 64 were male (79%) and 17 were
female (21%). Very elderly patients included 11 females
and 9 males. Of the 17 patients for whom histological
diagnosis of NSCLC was not possible, 13 were very eld-
erly. Among all patients, 61 (75%) were assessed as inoper-
able, and only 4 very elderly patients were considered
medically operable.
Treatment methods
SBRT was performed with 6 MV X-rays using a
CLINAC C21EX linear accelerator (2006–2009; Varian
Medical Systems, Palo Alto, CA, USA) or a Novalis Tx lin-
ear accelerator (2010–2012; BrainLAB, AG, Germany). A
CT simulator and a 3D radiotherapy planning system
(ECLIPSE, Version 6.5, 7.5; Varian Medical Systems) were
used to plan treatments for all patients. A BlueBAG sys-
tem (Medical Intelligence, Munich, Germany) was used to
immobilize patients. To maintain tumor positions during
irradiation, patients were instructed in the self-controlled
breath-hold technique using an Abches (APEX Medical,
Tokyo, Japan) respiratory monitoring system [20]. This
system was used during CT scanning for treatment plan-
ning and irradiation, and breath was held at inspiration or
expiration. CT data sets comprised 3 scans for each pa-
tient, with a slice thickness of 2.5 mm. For patients who
were unable to hold their breath long enough, irradiation
was performed and CT images for treatment planning
were obtained under normal breathing during both ex-
piratory and inspiratory phases. Data sets were combined,
and gross tumor volumes (GTV) were contoured for each
patient. Clinical target volumes (CTV) were equal to GTV
and the internal target volume (ITV) was the sum of
CTV. Planning target volumes (PTV) were determined by
adding 3- to 5-mm margins around the ITV, with a leaf
margin of 5 mm. Prescription doses of 48 Gy were
Table 1 Patient and tumor characteristics by age group (very elderly and younger status)
All Very elderly ≥ 85 years Younger < 85 years p value
(n = 81) (n = 20) (n = 61)
Age (years)
Median (range) 80 (64–93) 86 (85–93) 78 (64–84)
Gender 0.002*
Female 17 9 8
Male 64 11 53
Performance status (ECOG) 0.44
0/1/2/3/4 55/24/2/0/0 14/6/0/0/0 41/18/2/0/0
T stage 0.57
T1a/T1b/T2a 42/21/18 9/7/4 33/14/14
Histology 0.62
Adenocarcinoma 35 11 24
Squamous cell carcinoma 27 5 22
Unclassified NSCLC 2 0 2
Unproven 17 4 13
Tumor location 0.64
Central/Peripheral 6/75 1/19 5/56
Tumor opacity 0.41
Solid/GGO 79/2 20/0 59/2
Operability 0.49
Operable/Inoperable 21/60 4/16 17/44
Breath-hold 0.02*
Yes/No 50/31 8/12 42/19
Total dose 0.49
48 Gy/60 Gy 60/21 16/4 44/17
CTV (cc) 0.92
Mean ± SD (range) 19.5 ± 18.5 (1.1–91) 19.1 ± 19.3 (2.5–68) 19.7 ± 18.4 (1.1–91)
PTV (cc) 0.46
Mean ± SD (range) 69.1 ± 49.7 (9.3–224) 76.3 ± 65.4 (14.3–224) 66.8 ± 43.8 (9.3–205)
V20 (%) 0.64
Mean ± SD (range) 5.9 ± 3.2 (1.5–16) 6.2 ± 3.3 (1.6–14.9) 5.8 ± 3.2 (1.5–16)
MLD (Gy) 0.30
Mean ± SD (range) 3.9 ± 1.6 (1.2–9.2) 4.2 ± 1.5 (1.6–7.6) 3.8 ± 1.6 (1.2–9.2)
Abbreviations: ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung cancer, GGO ground-glass opacity, CTV clinical target volumes, PTV planning
target volumes, V20 volumes of normal lung tissue exposed to ≥ 20 Gy, MLD mean lung doses.
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using 8–11 conformal static ports, and patients were
treated biweekly. For tumors located centrally or adjacent
to critical organs with large CTV, the prescribed dose was
a total of 60 Gy in 10 fractions over 3 weeks. Dose calcula-
tions were performed using the convolution method, and
the Batho power-law method was used to correct for tis-
sue heterogeneities. Dose constraints for organs at risk
were maintained on the basis of the criteria described by
JCOG 0403 [19,21].Evaluation
Follow-up after SBRT comprised CT scans at 1 month,
and then at 3-month intervals for the first 2 years.
Thereafter, follow-up CT scans were performed every
4 months. Local recurrence was diagnosed according to
pathological confirmation, high uptake on FDG-PET
(SUVmax ≥ 8) [22,23], enlargement of tumor size, or the
presence of a mass-like consolidation shadow with dis-
appearance of air bronchogram [24,25]. Toxicity was
evaluated using the Common Terminology Criteria for
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29.0 months, ranging from 5.0 to 84.0 months (median
22.5 months) in patients aged ≥ 85 years, and was
30.0 months for all patients < 85 years.
Statistical analysis
Continuous quantitative variables were compared using
Student’s t test, ordinal quantitative variables were com-
pared using Mann–Whitney U test, and qualitative vari-
ables were compared using chi-squared test with Fisher’s
exact test. The Kaplan–Meier method was used to calcu-
late local control (LC), overall survival (OS), cause-specific
survival (CSS), and progression-free survival (PFS) rates,
and group comparisons were made using the log-rank test.
The Cox proportional hazard model was used to identify
predictors of OS in both univariate and multivariate ana-
lyses. Multivariate analyses were performed for variables
with probability (p) values of < 0.20 in univariate analysis,
and differences were considered significant when p < 0.05.
All statistical analyses were performed using StatView
software version 5.0 (SAS Institute, Cary, NC, USA).
Results
Patient and tumor characteristics
Table 1 summarizes the pretreatment characteristics of
81 patients, and tumors from very elderly (≥85 years)
and younger (<85 years) patients. Numbers of femalesFigure 1 Local control and survival according to Kaplan–Meier metho
(c) cause-specific survival (CSS) curve, and (d) progression-free survival (
elderly patients (age ≥ 85 years; n = 20); dotted line, younger patients (a
between very elderly and younger groups (p = 0.03). There were no signwere significantly greater in the very elderly group than
in the younger group (p = 0.002). Numbers of patients
who were capable of self-controlled breath-holding dur-
ing irradiation were significantly fewer in the very elderly
group than in the younger group (p = 0.02). CTV were
similar in each group, whereas PTV, V20 (the percentage
of the normal lung volume, after subtracting PTV fol-
lowing radiation with ≥ 20 Gy), and mean lung doses
(MLD) were slightly but insignificantly greater in the
very elderly group than in the younger group. No other
significant differences were found between the groups.
Local control and survival
Among all 81 patients, 1-, 2-, and 3-year LC rates were
97.4%, 95.9%, and 91.8%, respectively, and did not differ
significantly between very elderly and younger patient
groups (95.0%, 95.0%, and 83.1%, and 98.2%, 96.4%, and
93.8% , respectively; Figure 1a and Table 2). Among all
patients, 1-, 2-, and 3-year OS rates for all patients were
95.1%, 82.9%, and 69.4%, respectively. These were sig-
nificantly shorter among very elderly patients (95.0%,
71.2%, and 40.7%, respectively) than in the younger
group (95.1%, 86.4%, and 75.0%, respectively; p = 0.0306;
Figure 1b and Table 2). Among all patients, 1-, 2-, and
3-year CSS rates were 97.5%, 87.8%, and 77.9%, respect-
ively, and did not differ significantly between very elderly
(100%, 88.2%, and 50.4%, respectively) and youngerd. (a) local control (LC) curve, (b) overall survival (OS) curve,
PFS) curve. Bold solid line, all patients (n = 81); thin solid line, very
ge < 85 years; n = 61). Significant differences in OS were found
ificant differences in LC, CSS, or PFS between the groups.
Table 2 Local control and survival rates
1 year (%) 2 years (%) 3 years (%) p value
Local control for all
patients


























survival for all patients








Table 3 Summary of univariate analyses of overall
survival
Parameters n Hazard ratio (95% CI) p value
Age 1.05 (0.98–1.12) 0.19*
Gender
Female 17 1 0.72
Male 64 1.21 (0.52–3.65)
PS (ECOG)
0 55 1 0.61
1–2 26 1.23 (0.42–3.65)
T stage
T1a 42 1
T1b, T2a 39 2.38 (1.05–5.39) 0.04*
CTV 1.01 (1.00–1.03) 0.05*
PTV 1.00 (0.99–1.01) 0.29
Histology 0.78
Adenocarcinoma 35 1
Squamous cell carcinoma 27 1.46 (0.47–4.57) 0.51
Unproven 17 1.18 (0.35–3.92) 0.79
Tumor location
Peripheral 6 1
Central 75 1.29 (0.30–5.51) 0.73
Operability
Yes 21 1
No 60 1.03 (0.43–2.43) 0.94
Total dose
48 Gy 60 1
60 Gy 21 0.99 (0.93–1.07) 0.87
Abbreviations: ECOG Eastern Cooperative Oncology Group,
CIconfidence interval.
*p < 0.2.
Table 4 Summary of multivariate analysis
Variables Hazard ratio (95% CI) p value
Age 1.05 (0.98–1.12) 0.19
T stage (T1a vs. T1b, T2a) 2.41 (1.05–5.50) 0.04*
Abbreviations: CI confidence interval.
*p < 0.05.
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and Table 2). Similarly, 1-, 2-, and 3-year PFS rates for
all patients were 88.9%, 75.5%, and 59.5%, and did not
differ between very elderly (90.0%, 65.2%, and 44.7%, re-
spectively) and younger patients ( 88.5%, 78.3%, and
63.5%, respectively; Figure 1d and Table 2).
Univariate and multivariate analyses of predictors of
OS in all patients are shown in Table 3, and age, gender,
performance status, T stage (T1a vs. T1b or T2a), CTV,
PTV, histology, tumor location, operability, and total
doses were identified as independent variables. However,
in univariate analyses, only age, CTV, and T stage were
correlated with OS, with p values of < 0.20. Because
CTV was strongly related to T stage, subsequent multi-
variate analyses were performed with only age and T
stage, and T stage was significantly correlated with OS
(p = 0.04; Table 4).
Toxicity
SBRT was well tolerated, and all patients completed the
scheduled irradiation course without hospitalization.
Grades 2 and 3 RP developed in 7 (8.6%) and 2 (2.5%)
patients, respectively. In the very elderly and younger
groups, grade 2 RP was observed in 4 (20%) and 3 (10%)
patients, and grade 3 RP was observed in 2 (10%) and 0
(0%) patients, respectively. No patients suffered fromgrade 4 or 5 toxicity. However, RP was more severe in the
very elderly group than in the younger group (p = 0.002;
Table 5). In multivariate analyses of RP grade, age, CTV,
PTV, V20, and MLD, age was significantly related to the
severity of RP (p = 0.018), whereas CTV, PTV, V20, and
MLD were not. However, V20 and MLD showed predict-
ive tendencies for the severity of RP, with p values of 0.054
and 0.052, respectively (Table 6). Late toxicities included
CT diagnosed rib fractures in 15 (18.5%) of 81 patients
(5 (25%) in the very elderly group and in 10 patients
(16.3%) of the younger group. Only 2 patients (2.4%) in







(n = 81) (n = 20) (n = 61)
Radiation pneumonitis
≥ Grade 2 9 (11.1%) 6 (30%) 3 (4.9%) 0.002*
Grade 2 7 (8.6%) 4 (20%) 3 (4.9%)
Grade 3 2 (2.5%) 2 (10%) 0
Rib fracture 15 (18.5%) 5 (25%) 10 (16.3%) 0.41
*p < 0.05.
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Rib fracture rates did not differ significantly between
age groups (Table 5). Other adverse events included
nonmalignant pleural effusion in 5 patients (2 very elderly
patients and 3 and younger patients), atelectasis in 3 youn-
ger patients, and pneumothorax in 1 younger patient.
Discussion
Elderly populations are growing in many countries, in-
cluding Japan. Although lung cancer is a leading cause
of death, patients aged ≥ 80 years account for only 14%
of all lung cancer patients [26]. Because the life expect-
ancy of Japanese at birth was 83 years in 2011 for both
sexes, and because men and women who are 85 years
old are expected to live for an additional 6.0 and
8.1 years, respectively, radical treatment should be con-
sidered for elderly patients [18]. Surgery is the standard
treatment for stage I NSCLC. However, elderly patients
are often unsuitable for surgery and prefer non-surgical
options. The prognosis for untreated stage I NSCLC is
poor, with a median survival period of only 13 months
[27]. Radiotherapy is considered a curative alternative
for these patients, primarily because reported outcomes
of SBRT are similar to those of surgery [28]. Accordingly,Table 6 Radiation pneumonitis according to grade
All Grade
(n = 81) (n = 7
Age (years)
median (range) 80 (64–93) 80 (64
CTV (cc)
median (range) 12.4 (1.1–91) 12.4 (
PTV (cc)
median (range) 57.0 (9.3–224) 55.9 (
V20 (%)
median (range) 5.3(1.5–16) 5.1 (1
MLD (Gy)
median (range) 3.8 (1.2–9.2) 3.75 (
*p < 0.05.SBRT is often the primary treatment option for patients
with stage I NSCLC who are medically inoperable or re-
fuse surgery, and Palma et al. [29] proposed SBRT as the
standard care for inoperable elderly patients.
The median age of patients receiving SBRT for stage I
NSCLC in Japanese institutions is 76–78 years [14-17],
but was 80 years in the current study, which may reflect
the rural location of our hospital. Significantly more
women were aged ≥ 85 years than men, reflecting the
well known longer average life span of women than
men. In this study, we used a self-controlled breath-hold
technique to reduce ITV and PTV. However, patients in
the very elderly group could not hold their breath for a
sufficient period of time, leading to slightly but insignifi-
cantly higher mean PTV, V20, and MLD values in the
very elderly group. No other significant differences in
patients or tumor characteristics were found between
very elderly and younger patient groups.
Several recent studies show that SBRT is an effective
treatment, causing only minimal toxicity in elderly pa-
tients with NSCLC (Table 7), and leads to excellent 3-
year LC rates of 82.3%–100% [9,11,12]. In the present
study, LC rates were 83.1% and 93.8% among very eld-
erly and younger patients, respectively, but did not differ
significantly between the groups. LC rates for inoperable
patients receiving SBRT for stage I NSCLC were report-
edly between 83.0% and 97.6% at 3 years [5-7], and this
was similar among elderly patients.
The OS rate for all 81 patients was 69.4% at 3 years,
and 1-, 2-, and 3-year OS rates in the very elderly group
were 95.0%, 71.2%, and 40.7%, respectively. Although
these rates were significantly lower than in the very elderly
group, CSF rates did not differ between the groups. Eight
patient deaths occurred in the elderly group during the
present observation period. Among these, 4 were due to
lung cancer (1 with local failure and distant metastases, 2
were due to distant metastases only, and 1 was due tos 0, 1 Grades 2, 3 p value
2) (n = 9)
–88) 85 (70–93) 0.018*
1.1–61.8) 14.8 (2.9–91) 0.49
9.3–224) 57.6 (22.7–215) 0.43
.5–16) 6.8 (3.7–11.1) 0.054
1.2–9.2) 4.8 (2.9–6.9) 0.052
Table 7 Studies of stereotactic body radiotherapy for stage I NSCLC in the elderly
Author Age (range) n T stage Doses Local control Overall survival
Haasbeek CJ et al. [9] ≥ 75 (75–91) 193 T1 118 60 Gy/3 fr 89% at 3 years 45% at 3 years
T2 85 60 Gy/5 fr
60 Gy/8 fr
Takeda A et al. [12] ≥ 80 (80–91) 109 T1a 32 50 Gy/4 fr 82.3% at 3 years 53.7% at 3 years
T1b 35 40 Gy/ 5 fr
T2 42
Sandhu AP et al. [11] ≥ 80 (80–89) 24 T1 18 48 Gy/4 fr 100% 74% at 2 years
T2a 6 56 Gy/5 fr (4.3–61.2 months)
This study ≥ 85 (85–93) 20 T1a 9 48 Gy/4 fr 83.1% at 3 years 71.2% at 2 years
(Hayashi S et al.) T1b 7 60 Gy/10 fr 40.7% at 3 years
T2a 4
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lated illnesses (2 of heart failure, 1 of cerebral infarction,
and 1 of pneumonia that was not related to radiation
pneumonitis). Thus, very elderly patients tended to die of
causes other than NSCLC.
Prognostic factors for OS that were identified in uni-
variate analysis included age, T stage (T1a vs. others),
and CTV. However, in subsequent multivariate analyses,
only T stage was a significant prognostic factor for OS,
indicating that tumor size is a stronger prognostic factor
than age. In agreement, Palma et al. [30] showed that
survival after radical treatment (radical radiotherapy or
surgery) for stage I NSCLC is dependent on tumor stage
but not age. They also suggested that elderly patients
should not be excluded from radical treatments based
on age alone. Moreover, T stage (T1a vs. T1b or T2a),
tumor diameter, and sex were previously reported as sig-
nificant prognostic factors for NSCLC following SBRT
[31,32]. In the present study, prognostic factors were not
evaluated in the very elderly due to low patient numbers
and limitations of natural life span. Takeda et al. [12] re-
ported predictors of short OS in medically inoperable
patients aged ≥ 80 years, including low body mass index,
high T stage, and high C-protein level. The present data
also show that operability was not a significant prognos-
tic factor. However, because this is assessed by multidis-
ciplinary boards, a bias may exist between institutions.
Nonetheless, 4 very elderly operable patients remained
alive without recurrence during the observation period
(18–36 months). In this study, we did not analyze factors
associated with FDG-PET because not all patients were
assessed using this procedure. However, we previously
reported that pretreatment SUVmax values from FDG-
PET or CT were predictive of disease-free survival in
SBRT-treated patients with pathologically or cytolo-
gically confirmed stage I NSCLC [22]. However, some
reports show no relationship between SUVmax andSBRT treatment outcomes for NSCLC [33,34]. Thus,
the prognostic value of SUVmax in these patients re-
mains controversial.
Toxicity of SBRT is primarily related to RP. However,
whereas grades 2 and 3 RP reportedly occur in 4.6%–13.8%
and 0%–20% of patients, respectively [7,9-11,19,2,30,31],
reported rates of grade 4 and 5 RP are very low. According
to a survey of SBRT in Japan, grade 5 RP occurs in 0.6% of
cases and is predominantly associated with interstitial
pneumonia [21,35]. Similarly, among the present patients,
rates of grades 2 and 3 RP were 8.5% and 2.5%, respect-
ively, and no grade 4 or 5 RP was observed. However,
grades 2 and 3 RP were observed in 20% and 10% of very
elderly patients, respectively. Severe RP was observed
more frequently in the very elderly group than in the
younger group. However, no younger patients, and only
two very elderly patients, suffered from grade 3 RP, and
the severity of RP was significantly correlated with age.
The incidence of ≥ grade 2 RP in the very elderly group
was greater than that reported in other studies of elderly
patients (Table 7). However, previous reports included pa-
tients aged ≥ 75 or 80 years, and and did not include data
from patients aged ≥ 85 years. Nonetheless, the increased
severity of RP among very elderly patients may reflect re-
duced cardiopulmonary functions and physical conditions.
PTV, V20, and MLD are reportedly risk factors for RP in
SBRT treated patients with NSCLC [30,36-38]. In the
present study, CTV values were similar between the
groups, whereas PTV, V20, and MLD values were slightly
higher in the very elderly group, and V20 and MLD were
almost significant predictors of RP severity (Table 6). Very
few of the present elderly patients were able to perform
the breath-hold technique sufficiently to maintain tumor
position during irradiation and reduce the volume of irra-
diated healthy lung tissue, which may have increased PTV,
V20, and MLD values. Hence, efforts to decrease these
values should be prioritized to reduce the risk of RP using
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gating or real-time tumor-tracking radiation therapy
systems [31,39].
Rib fracture was observed on follow-up CT in 18.5% of
all patients (25% in the very elderly group and 16.3% in
the younger group). Only two (2.4%) patients in the youn-
ger group complained of chest pain, and no patients ex-
hibited symptoms of grade 3 or more. All elderly patients
with rib fractures were asymptomatic, and no significant
differences in rib fracture rates were found between the
groups. In a study by Nambu et al. [40], rib fractures oc-
curred in 23.2% of patients, and pain to the chest wall was
reported in 10.2% of patients. The rib fracture rate in the
current study was much higher than that reported in other
studies of elderly patients, but was similar to that reported
by Nambu et al. [40]. Potentially, the follow-up period,
tumor locations, and parameters of CT scanning may have
increased rib fracture rates in the present study. Previous
studies showed that female gender, lateral tumor location,
small tumor-chest distance, doses to 8 cc of the chest wall,
and doses to 2 cm3 of the rib were significant prognostic
factors for rib fracture [41-43], However, age was not a
risk factor for rib fracture in the present study, and symp-
toms were generally mild or asymptomatic if present.
Thus, rib fracture is not a major concern during treatment
of very elderly patients with SBRT.
Conclusion
SBRT for very elderly patients (age ≥ 85 years) with stage Ι
NSCLC was well tolerated and feasible, with comparable
efficacy to that observed in younger patients. Although
very elderly patients suffered significantly more severe
RP than younger patients, SBRT decreased V20 and
MLD and reduced the risk of RP in very elderly patients.
Although only 20 very elderly patients with NSCLC
were included, the present analyses indicate that SBRT
is curative, and warrant future studies with larger patient
numbers.
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